1. Hamrell MR. Preclinical considerations for life-threatening illnesses. Clin Res Reg Affs. 1992;9:225–232.
2. Bernstein DF. CTM’s unique requirements affect production approaches. Appl Clin Trials. 1999;8(3): 48–54.
3. International Conference on Harmonization. Good Clinical Practice: Consolidated Guideline. Federal Register May 9, 1997; Vol. 62, No. 90.
4. Hamrell MR, Horowitz AM. Understanding expanded access programs. Reg Aff. 1991;3:629–638.
5. Hamrell MR. New development strategies for life-threatening illnesses. BioPharm. 1992;5(6): 18–21.